Cas:915402-04-9 2-(4-methoxy-2,3-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane manufacturer & supplier

We serve Chemical Name:2-(4-methoxy-2,3-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane CAS:915402-04-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-(4-methoxy-2,3-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Chemical Name:2-(4-methoxy-2,3-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
CAS.NO:915402-04-9
Synonyms:2,3-Dimethyl-4-methoxyphenylboronic acid pinacol ester;4,4,5,5-TETRAMETHYL-2-(2,3-DIMETHYL-4-METHOXYPHENYL)-[1,3,2]DIOXABOROLANE;4-Methoxy-2,3-dimethylphenylboronic acid pinacol ester
Molecular Formula:C15H23BO3
Molecular Weight:262.15200
HS Code:2931900090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:27.69000
Exact Mass:262.17400
LogP:2.61120

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,3-Dimethyl-4-methoxyphenylboronic acid pinacol ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Methoxy-2,3-dimethylphenylboronic acid pinacol ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4,5,5-TETRAMETHYL-2-(2,3-DIMETHYL-4-METHOXYPHENYL)-[1,3,2]DIOXABOROLANE Use and application,4,4,5,5-TETRAMETHYL-2-(2,3-DIMETHYL-4-METHOXYPHENYL)-[1,3,2]DIOXABOROLANE technical grade,usp/ep/jp grade.


Related News: The most frequently reported adverse events for anifrolumab in the TULIP-1 and TULIP-2 trials were upper respiratory tract infection, bronchitis, infusion-related reactions and herpes zoster. N-(3-(4-phenylpiperidin-1-yl)propyl)-5-thia-1,2a1-diazaacenaphthylene-4-carboxamide manufacturers As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders. 2-(3-triethoxysilylpropyl)isoindole-1,3-dione suppliers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. 5-[1,3-dioxo-2-(3-triethoxysilylpropyl)isoindole-5-carbonyl]-2-(3-triethoxysilylpropyl)isoindole-1,3-dione vendor & factory.